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The mutational landscape of adenoid cystic carcinoma
(ACC) is currently being revealed, but further studies are
needed to identify biomarkers as therapeutic targets or
prognostic factors of ACC. In this study, we investigated
the expression of epithelial cell adhesion molecule
(EpCAM) in ACCs. We retrospectively collected 83 cases
of surgically resected ACCs. Using tissue microarray, we
conducted immunohistochemical staining using the anti-
EpCAM antibody. EpCAM expression was analysed by
intensity score and the total immunostaining score. The
positivity was 97.6% (81/83 cases), regardless of the
intensity score. A higher histological grade (p = 0.006)
and specific tumour location (non-salivary gland origin,
p = 0.02) showed a correlation with higher EpCAM in-
tensity. Higher EpCAM expression by total immuno-
staining score was associated with histological grade
(p = 0.004), distant metastasis (p = 0.004) and poorer
prognosis (overall survival p = 0.015 and progression-
free survival p = 0.033). We suggest EpCAM as a
candidate prognostic marker and a putative therapeutic
target in ACC. Also, ACCs arising from salivary gland
and non-salivary gland sites, respectively, might display
different pathophysiologies in which EpCAM could play a
role.
Key words: Adenoid cystic carcinoma; EpCAM; Ber-EP4; biomarker; non-
salivary gland.
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Adenoid cystic carcinoma (ACC) is an uncommon malig-
nancy of the secretory glands and often occurs in the areas of
the head and neck, particularly in the salivary glands.1 It is
characterised by indolent, persistent growth and frequent
perineural invasion, local recurrence and a poor long-term
prognosis.1,2
Immunohistochemical staining is often used to distinguish
ACC from other malignancies, especially when histological
ﬁndings are confusing. ACC expresses both ductal and
myoepithelial cell markers, such as CK7, CAM 5.2, calponin,
SMA, SMMHC, p63, SOX10, and S100, but their variable
expressions in ACC and other malignancies have made them
not useful for diagnosis.3,4 Currently, c-KIT is widely used as3025/Online ISSN 1465-3931 © 2018 Royal College of P
er the CC BY-NC-ND license (http://creativecommons.org
rg/10.1016/j.pathol.2018.08.013a diagnostic marker, because most ACCs are strongly posi-
tive for c-KIT regardless of the histological grade.3,4 Many
investigators have focused on this receptor as a therapeutic
target.5,6 However, clinical trials using imatinib, a c-KIT
inhibitor, have been unsatisfactory, and several studies have
shown that ACCs express wild-type c-KIT.7–10 Strong nu-
clear MYB expression, due to MYB-NFIB translocation, is
detected in up to 70% of ACCs regardless of the site of
tumour origin, and MYB appears to be a valuable diagnostic
marker for ACC.11–13 MYB-NFIB translocation seems to be
speciﬁc in ACC, and these aberrations may be a critical event
in ACC pathogenesis.14 However, further studies are needed
to uncover the application of MYB-associated genes in
therapy.
Epithelial cell adhesion molecule (EpCAM) is a 40 kDa
cell surface glycoprotein that is overexpressed in epithelial
cancers and, at lower levels, in normal epithelium; therefore,
it is considered a tumour marker.15 It consists of a large
extracellular domain of 242 amino acids (aa), a single-
spanning transmembrane domain of 23 aa and a short cyto-
plasmic domain of 26 aa. The function of EpCAM includes
intercellular adhesion, cell proliferation, signalling, migration
and differentiation.
EpCAM is overexpressed in certain carcinomas, including
colon, pancreas, and breast carcinomas.16–18 The high levels
of EpCAM in some cancers are related to a poor prognosis,
and EpCAM can serve as a prognostic marker. Therefore, the
overexpression of EpCAM in tumours makes it an attractive
therapeutic target. In the context of skin cancer, EpCAM has
been used for diagnostic purposes: the anti-EpCAM antibody
Ber-EP4 is a sensitive marker of basal cell carcinoma.19–21
Studies regarding EpCAM expression in ACC are rela-
tively scarce. Given the potential diagnostic and therapeutic
applications of anti-EpCAM antibodies, we investigated the
expression of EpCAM in ACCs. The purpose of this study
was to demonstrate the expression of EpCAM in ACC and to
verify the clinicopathological features of ACC according to
the expression level of EpCAM.
MATERIALS AND METHODS
Case selection
We included 83 patients with ACC who underwent surgical resection from
1996 to 2013 at Severance Hospital, Korea. Clinical data, including gender, age
at diagnosis, tumour location, disease recurrence, metastasis, and survival of
patients, were obtained from the patients’ medical records. The histological
grades of the tumours and perineural invasion were noted from the review of
slides and pathology reports. All slides were retrospectively reviewed by twoathologists of Australasia. Published by Elsevier B.V. This is an open
/licenses/by-nc-nd/4.0/).
Fig. 1 Examples of the intensity levels of EpCAM in ACC. (A) Negative, 0. (B) Weak, 1+. (C) Moderate, 2+. (D) Strong, 3+.
738 LEE et al. Pathology (2018), 50(7), Decemberpathologists (LSJ and KSK), and histological evaluation was conducted on
haematoxylin and eosin (H&E) stained slides. Histological grade was evaluated
using the grading system of Perzin/Szanto as follows: 1, predominantly tubular
and cribriform component, no solid pattern; 2, predominantly cribriform
component or mixed, <30% solid component; 3, marked predominance of the
solid component.22,23 All methods and experimental protocols using human
tissue [formalin ﬁxed, parafﬁn embedded (FFPE) tissue] were carried out in
accordance with relevant guidelines and regulations approved by the Institu-
tional Review Board of Severance Hospital, Yonsei University Health System
(4-2015-0872). The informed consent was waived because the IRB decided that
this retrospective study showed minimal risk to the patients (risk level I).
Tissue microarray analysis
A representative area was selected on each H&E slide, and a corresponding
spot was marked on the surface of the FFPE block. Using a biopsy needle, the
selected area was punched out, and a 3 mm tissue core was placed into a 6 × 5
recipient block. Each tissue core was assigned to a unique tissue microarray
location number linked to a database containing other clinical data.
Immunohistochemistry
FFPE tissue blocks were cut into 4 mm sections. Immunohistochemical
staining was performed using a Ventana XT automated stainer (Ventana
Corporation, USA) with antibodies against EpCAM (clone VU-1D9, 1:1,000;
Calbiochem, USA), according to the manufacturer’s instructions. Negative
control samples were processed without the primary antibody. Positive con-
trol tissue was used as per the manufacturer’s recommendation.
The expression of EpCAM was semiquantitatively evaluated by intensity
score (IS) analysis and by calculating the total immunostaining score (TIS),
the product of the intensity score and proportion score (PS). IS represents theTable 1 Correlation between EpCAM expression by intensity score (IS), total im
n EpCAM expression (IS)
Negative (0)
n (%)
Weak (1+)
n (%)
Moderate (2+
n (%)
Age (years) 83
50 31 1 (3.2) 24 (77.4) 3 (9.7)
>50 52 1 (1.9) 33 (63.5) 11 (21.2)
Gender
Male 29 2 (6.9) 19 (65.5) 7 (24.1)
Female 54 0 (0) 38 (70.4) 7 (13.0)
Location
Salivary gland 53 0 (0) 42 (79.2) 6 (11.3)
Others 30 2 (6.7) 15 (50.0) 8 (26.7)
Histological grade
Grade 1 19 2 (10.5) 14 (73.7) 3 (15.8)
Grade 2 48 0 (0) 36 (75.0) 8 (16.7)
Grade 3 16 0 (0) 7 (43.8) 3 (18.8)
Perineural invasion
Present 61 1 (1.6) 41 (67.2) 11 (18.0)
Absent 22 1 (4.5) 16 (72.7) 3 (13.6)
Local recurrence
Present 20 0 (0) 12 (60.0) 3 (15.0)
Absent 63 2 (3.2) 45 (71.4) 11 (17.5)
Distant metastasis
Present 30 1 (3.3) 17 (56.7) 4 (13.3)
Absent 53 1 (1.9) 40 (75.5) 10 (18.9)estimated staining intensity compared with that of control cells (0, no staining;
1, weak; 2, moderate; 3, strong), and PS describes the estimated area of
positively stained tumour cells (0, none; 1, <10%; 2, 10–50%; 3, 51–80%; 4,
>80%). TIS (IS*PS) ranges from 0 to 12 with only nine possible values (0, 1,
2, 3, 4, 6, 8, 9 and 12). Using TIS, we deﬁned the low-expression group (TIS
0–8) and high-expression group (TIS 9 and 12).
To see the cellular distribution of EpCAM, the expression pattern (mem-
branous or cytoplasmic) was analysed.
Statistical analysis
All statistical analyses were performed using SPSS software, version 21.0 for
Windows (IBM, USA). To analyse each clinicopathological parameter, Stu-
dent’s t-test, Fisher’s exact test and Pearson’s c2-test were used, depending on
the purpose. Patient survival statistics were analysed using the Kaplan–Meier
method and log-rank test, and uni- and multivariate analyses were performed
using the Cox regression model. Hazard ratios (HRs) and corresponding 95%
conﬁdence intervals (CIs) were presented. p < 0.05 was considered to indicate
statistical signiﬁcance.
RESULTS
Clinicopathological characteristics
This study included 83 patients with ACC: 53 cases (63.9%)
arose from the salivary gland (46 cases from the major sali-
vary gland and seven cases from the minor salivary gland),
and 30 cases (36.1%) arose from the non-salivary gland site,
including the lacrimal gland, orbit, nasal cavity, pharynx,
larynx, auditory canal, breast and trachea. The mean age ofmunostaining score (TIS) analyses and clinicopathological parameters
p value EpCAM expression
(TIS)
p value
) Strong (3+)
n (%)
TIS  8
n (%)
TIS > 8
n (%)
0.464 0.737
3 (9.7) 28 (90.3) 3 (9.7)
7 (13.5) 45 (86.5) 7 (13.5)
0.064 0.154
1 (3.4) 28 (96.6) 1 (3.4)
9 (16.7) 45 (83.3) 9 (16.7)
0.020 0.484
5 (9.4) 48 (90.6) 5 (9.4)
5 (16.7) 25 (83.3) 5 (16.7)
0.006 0.004
0 (0) 19 (100.0) 0 (0.0)
4 (8.3) 44 (91.7) 4 (8.3)
6 (37.5) 10 (62.5) 6 (37.5)
0.769 1.000
8 (13.1) 53 (86.9) 8 (13.1)
2 (9.1) 20 (90.9) 2 (9.1)
0.234 0.056
5 (25.0) 15 (75.0) 5 (25.0)
5 (7.9) 58 (92.1) 5 (7.9)
0.014 0.004
8 (26.7) 22 (73.3) 8 (26.7)
2 (3.8) 51 (96.2) 2 (3.8)
Fig. 2 Survival analysis according to the EpCAM expression pattern (TIS  8 or TIS > 8) in ACC patients. (A) Overall survival (p = 0.015). (B) Progression-free
survival (p = 0.033).
EXPRESSION OF EPCAM IN ADENOID CYSTIC CARCINOMA 739the patients was 53.2 years (age range 20–81 years), and the
male-to-female ratio was 1:1.9. According to the histological
grade, 19 cases (22.9%) demonstrated grade 1, 48 cases
(57.8%) demonstrated grade 2, and 16 cases (19.3%)
demonstrated grade 3.
EpCAM expression in ACC
The expression of EpCAM in normal salivary gland tissue
was negative or weakly positive in acinar and ductal cells, as
previously reported.24 Positive staining of EpCAM occurred
primarily on the cell membrane and cytoplasm (Fig. 1). The
correlation between EpCAM expression by IS, TIS and
clinicopathological parameters is listed in Table 1.
The positivity was 97.6% (81/83 cases), regardless of the
intensity score (IS). Negative expression of EpCAM was
identiﬁed in two cases (2.4%), weak expression in 57 cases
(68.7%), moderate expression in 14 cases (16.9%), and
strong expression in 10 cases (12.0%). The number in the
low-expression group by TIS was 73 (88.0%) and in the high-
expression group was 10 (12.0%). No signiﬁcant differenceTable 2 Univariate and multivariate analyses of clinicopathological variables and E
in patients with ACC
Risk factors Univariate analysis
HR 95% CI
Overall survival
Age (50/>50) 1.248 0.533–2.920
Gender (male/female) 0.339 0.151–0.765
Location (others/salivary) 0.894 0.410–1.950
Histological grade (1+2/3) 3.170 1.431–7.021
Perineural invasion (N/P) 4.058 0.953–17.280
Local recurrence (N/P) 2.201 0.977–4.959
Distant metastasis (N/P) 3.005 1.314–6.873
EpCAM IS (0–2/3) 2.998 1.183–7.583
Progression-free survival
Age (50/>50) 0.902 0.491–1.658
Gender (male/female) 0.467 0.258–0.847
Location (others/salivary) 0.876 0.481–1.593
Histological grade (1+2/3) 2.131 1.113–4.081
Perineural invasion (N/P) 3.013 1.272–7.139
Local recurrence (N/P) 3.046 1.671–5.553
Distant metastasis (N/P) 7.345 3.772–14.301
EpCAM IS (0–2/3) 2.247 1.039–4.858
CI, conﬁdence interval; HR, hazards ratio; IS, intensity score; N/P, negative versuswas identiﬁed between EpCAM intensity and certain clini-
copathological parameters such as age at diagnosis, gender,
perineural invasion and local recurrence. However, tumour
location (non-salivary gland origin, p = 0.02), higher histo-
logical grade (p = 0.006) and distant metastasis (p = 0.014)
were related to higher expression of IS. By TIS, a higher
EpCAM expression level was also related to the histological
grade (p = 0.004) and frequent distant metastasis (p = 0.004).
Survival analysis
Kaplan–Meier and Cox regression analyses were
performed to discover a link between EpCAM expression
in ACC and patient survival. In the Kaplan–Meier analysis,
there was a relationship in the patients with higher EpCAM
expression (TIS > 8) who had poorer overall survival (OS)
and progression-free survival (PFS) than those with a lower
TIS level (TIS  8) (OS, p = 0.015 and PFS, p = 0.033)
(Fig. 2). According to Cox regression analysis, the vari-
ables with a signiﬁcant difference in OS rates were male
gender (p = 0.009), higher histological grade (p = 0.004),pCAM expression in relation to overall survival and progression-free survival
Multivariate analysis
p value HR 95% CI p value
0.610 0.670 0.258–1.741 0.411
0.009 0.277 0.095–0.803 0.018
0.778 1.840 0.745–4.546 0.186
0.004 2.146 0.915–5.031 0.079
0.058 2.164 0.448–10.462 0.337
0.057 1.525 0.555–4.192 0.413
0.009 2.045 0.873–4.793 0.100
0.021 2.908 0.896–9.440 0.076
0.741 0.599 0.299–1.200 0.148
0.012 0.893 0.399–2.000 0.784
0.664 1.879 0.938–3.766 0.075
0.023 0.970 0.464–2.030 0.936
0.012 2.035 0.794–5.219 0.139
<0.001 3.088 1.668–5.717 <0.001
<0.001 7.611 3.841–15.083 <0.001
0.040 0.956 0.344–2.655 0.932
positive
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sion (p = 0.021) in the univariate analysis (Table 2).
EpCAM expression did not affect the OS of ACC patients
in the multivariate analysis.
In univariate analysis for PFS, male gender (p = 0.012),
higher histological grade (p = 0.023), perineural invasion
(p = 0.012), local recurrence (p < 0.001), distant metastasis
(p < 0.001) and strong EpCAM expression (p = 0.04) were
statistically signiﬁcant. In the multivariate analysis, EpCAM
expression did not affect the PFS. Local recurrence and
distant metastasis were identiﬁed as independent prognostic
factors for PFS. All the statistically signiﬁcant variables
were subjected to the Cox proportional hazards regression
model.
DISCUSSION
Several studies have investigated the expression of EpCAM
in various carcinomas. Although EpCAMmight be expressed
weakly on normal epithelium, it is overexpressed in tumours,
including colorectum, oesophagus, liver, prostate, lung,
pancreas and breast tumours.18 EpCAM overexpression is
associated with poorer prognosis in carcinomas of the breast,
gallbladder, ovary, ampulla and oesophagus because the
molecule functions as an inhibitor of E-cadherin; therefore, it
is believed that EpCAM plays a role in metastasis.25–31 On
the other hand, EpCAM can participate in cell adhesion, and
its overexpression is suggested to be linked to better survival
in patients with colorectal carcinoma, gastric carcinoma, clear
cell renal cell carcinoma and non-small cell lung cancer.32–36
We performed immunohistochemical staining of EpCAM
on the tissues of 83 ACC samples. Some reports have sug-
gested that the cellular distribution of EpCAM varies by
tumour type and histological differentiation of carcinoma;
therefore, it might have diagnostic value.37,38 However, we
identiﬁed both membranous and cytoplasmic expression in
cancer cells of ACC and it does not have any clinicopatho-
logical signiﬁcance in ACC.
In this study, we found that the overexpression pattern of
EpCAM in ACC is associated with a higher histological
grade. Furthermore, we could conﬁrm that EpCAM plays a
role in tumour distant metastasis in the context of ACC, as
previous studies have suggested in other tumours.25–31
Phattarataratip et al. studied epithelial cell adhesion mole-
cule expression in various salivary gland neoplasms, including
mucoepidermoid carcinoma, adenoid cystic carcinoma, pleo-
morphic adenoma, and polymorphous low-grade adenocarci-
noma.39 They included EpCAM and showed different
EpCAM expression patterns among salivary gland neoplasms.
They demonstrated that decreased EpCAM expression was
associated with aggressive features in mucoepidermoid carci-
noma, and the ACCs showed negative or weakly positive
immunoreactivity to EpCAM, contrary to our result. However,
that previous study possessed some limitations in that the
number of ACC cases involved in the study was too small and
they found that the solid growth area of ACC showed diffuse
and strong immunoreactivity to EpCAM.
By immunohistochemistry, the stronger EpCAM staining
intensity was more frequently observed in ACCs arising from
non-salivary gland sites. We showed that tumour location
tends to affect ACC patients’ progression-free survival by
multivariate analysis. Lin et al. compared the ACCs of sali-
vary and non-salivary origin, and they also found thatsinonasal, lacrimal, and tracheobronchial ACCs had signiﬁ-
cantly worse outcomes than ACCs of the major salivary
glands.40 The different patients’ outcomes between salivary
and non-salivary sites of tumour may come from difﬁculties
of diagnosis and complete resection as well as different
tumour biologies, but further studies are required to clear
these differences according to tumour location.
A previous study investigated the expression of tumour-
associated calcium signal transducer 2 (TACSTD2, Trop2),
a homolog of EpCAM, in salivary ACC.41 Similar to our
result of EpCAM in ACC, TACSTD2 overexpression was
related to a poor prognosis in patients, although the molecule
did not reﬂect the histological subtype.
The possible prognostic signiﬁcance of EpCAM over-
expression in various cancers has been raised by several in-
vestigators.30,42–44 Similarly, overexpression of EpCAMwas
correlated with higher histological grade and distant metas-
tasis and we conﬁrmed strong EpCAM expression is an in-
dependent factor affecting ACC patients’ survival in the
statistical evaluation.
Several clinical trials using various anti-EpCAM antibodies
have been investigated despite the controversy. Catumaxomab
was approved in Europe to treat malignant ascites in patients
with EpCAM-positive carcinomas.45,46 Additionally, a few
studies using anti-EpCAM antibody showed that it might have
an anti-tumour effect.47–49 However, the validation of
EpCAM as a therapeutic target remains unexplored.
In conclusion, we demonstrated the expression of EpCAM
in ACC according to the various clinicopathological condi-
tions. A higher histological grade and speciﬁc tumour loca-
tion (non-salivary gland site) showed higher EpCAM
expression, and strong EpCAM positivity was associated
with distant metastasis and poorer prognosis. We believe that
this study will strengthen the basis for understanding the
pathophysiology of ACC and suggests EpCAM as a candi-
date molecule for a prognostic and therapeutic biomarker.
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